Step 1: - Joint Clinical Trials Office | Weill Cornell ...
Docx File 82.88KByte
The FDA conducts inspections to determine if clinical studies are being conducted in compliance with applicable statutory and regulatory requirements. Clinical investigators who conduct FDA-regulated clinical investigations are required to permit FDA investigators to access, copy, and verify any records or reports made by the clinical investigator. This document is intended to provide a step-by-step overview of what to expect before, during and after FDA Inspections.Contents TOC \o "1-3" \h \z \u Initial Notification of Inspection PAGEREF _Toc411435002 \h 1Notify Relevant Weill Cornell Medical College Personnel PAGEREF _Toc411435003 \h 2Reserve a Space for the Inspection PAGEREF _Toc411435004 \h 3Equipment Review PAGEREF _Toc411435005 \h 3Regulatory Review PAGEREF _Toc411435006 \h 4Clinical Review PAGEREF _Toc411435007 \h 7Day of Inspection PAGEREF _Toc411435008 \h 8After Inspection PAGEREF _Toc411435009 \h 9Additional Resources PAGEREF _Toc411435010 \h 9Step 1: Initial Notification of InspectionThe FDA can conduct both announced and unannounced inspections of clinical investigator sites. It is important to always be prepared for unannounced visits by following good clinical practices; however, in the event that announced visit is conducted, generally a telephone call is made to the site to schedule a visit. During the telephone conversation, it is highly encouraged to collect all of the information outlined in the table below. Information to Obtain Notes/CommentsDate FDA Contacted SiteFDA Inspectors InformationName:Title:Email: Phone: Name of PI Being InspectedName and Protocol # of Protocol(s) Being InspectedReason for Inspection (routine, random, high/low enrolling, for cause, etc.)Personnel to be Made Available for InspectionSpecific Documents to be Made Available for InspectionList Any Documents to be Sent to FDA Prior to Inspection Documents:Address/Email to Send Documents: Date, Time and Duration of InspectionDate: _______________________________ Time:_______________ Duration:________________*Note: All communication between site staff and FDA should be documented and filed in the relevant study binder.Step 2: Notify Relevant Weill Cornell Medical College PersonnelAt Weill Cornell Medical College the following entities and study personnel must be notified of any FDA inspection. Contact Date NotifiedConfirmed Availability to Attend InspectionComments/Action ItemsJoint Clinical Trials Office (JCTO)JCTOoperations@med.cornell.edu __YES __NO __N/AQuality Assurance Unit (QAU) firstname.lastname@example.org __YES __NO __N/AInstitutional Review Board (IRB)IRB@med.cornell.edu __YES __NO __N/AStudy Sponsor (if applicable)__YES __NO __N/AStudy Team:Principal InvestigatorSub-Investigator(s)Study Coordinator(s)Pharmacist Data ManagerLaboratory StaffAll Other Personnel Listed on Delegation LogAll Other Personnel Listed on FDA From 1572__YES __NO __N/A__YES __NO __N/A__YES __NO __N/A__YES __NO __N/A__YES __NO __N/A__YES __NO __N/A__YES __NO __N/A__YES __NO __N/AList Any Additional Staff Invited to Attend Inspection:__YES __NO __N/AStep 3: Reserve a Space for the InspectionReserving the proper location for your FDA inspection is important. The reserved location should be close to a copy machine and should not contain any records/files unrelated to the study. Staff member assigned to guide FDA Inspector should remain available for the Inspector during the entire visit.Reserved Location:Identify Personnel to Guide Inspector and Serve as Point of ContactName/Title:Contact Information:Step 4: Equipment ReviewIf applicable, ensure all of the following clinic equipment have been properly calibrated and provide up-to-date calibration records. Where applicable, confirm temperature logs are complete and current.Equipment TypeDate ReviewedComments/Action ItemsRefrigeratorsDouble-Locked: ___ Yes ___ No ___N/AFreezersDouble-Locked: ___ Yes ___ No ___N/AStudy Agent Storage Area/CabinetsDouble-Locked: ___ Yes ___ No ___N/AStudy Binder/Material Storage AreaDouble-Locked: ___ Yes ___ No ___N/AElectronic ScalesElectronic Blood Pressure CuffList All Study-Related Laboratory Equipment:Step 5: Regulatory Review Locate, compile, organize, and review the documents listed below for accuracy and completeness. Please contact the JCTO Quality Assurance Unit if you have any questions regarding the documents listed below (email@example.com). DocumentConfirm/CompleteComments/Action ItemsPrincipal Investigator CV (including list of all active protocols)___ Yes ___ No ___N/APrincipal Investigator Medical License___ Yes ___ No ___N/APrincipal Investigator Good Clinical Practice/Human Subjects Protection Training Documentation___ Yes ___ No ___N/APrincipal Investigator Financial Disclosure Form___ Yes ___ No ___N/ASub-Investigator(s) CV (including list of all active protocols)___ Yes ___ No ___N/ASub-Investigator(s) Medical License___ Yes ___ No ___N/ASub-Investigator(s) Good Clinical Practice/Human Subjects Protection Training Documentation___ Yes ___ No ___N/ASub-Investigator(s) Financial Disclosure Form___ Yes ___ No ___N/AStudy Staff CVs___ Yes ___ No ___N/AStudy Staff Relevant Licensure___ Yes ___ No ___N/AStudy Staff Good Clinical Practice/Human Subjects Protection Training Documentation___ Yes ___ No ___N/AStudy Staff Financial Disclosure Forms___ Yes ___ No ___N/AStudy Staff Protocol Training Log(s)___ Yes ___ No ___N/ADelegation Log/Signature Log___ Yes ___ No ___N/AComplete Subject Log (list of all subjects including name, contact information, enrollment and completion dates)___ Yes ___ No ___N/AScreening Log (names of all participants screened including enrollment date and reason for screen failure if applicable; ensure log is current and legible)___ Yes ___ No ___N/AEnrollment/Randomization Logs___ Yes ___ No ___N/AAll IRB-Approved Protocol Versions___ Yes ___ No ___N/AAll IRB-Approved Protocol Amendments, Clarifications, Amendments, and Study-Related Correspondence___ Yes ___ No ___N/AIRB-Approved Informed Consent (all versions)___ Yes ___ No ___N/AInvestigators Brochures/Package Inserts (all versions)___ Yes ___ No ___N/AIRB Initial Protocol Submission/Approval Letter___ Yes ___ No ___N/AIRB Amendment Submission/Approval Letter ___ Yes ___ No ___N/AIRB Continuing Review Submission/Approval Letter ___ Yes ___ No ___N/AIRB Approval Letter for Informed Consent___ Yes ___ No ___N/AIRB Approval Letter for Recruitment Materials___ Yes ___ No ___N/AIRB Correspondence Related to AE/SAE___ Yes ___ No ___N/AAll Correspondence Related to Any Protocol Deviations (to/from IRB/Sponsor)___ Yes ___ No ___N/ADSMB Reports (including submission to IRB)___ Yes ___ No ___N/ADocumentation of Protocol Registration, Submission, Activation, and Deregistration (if applicable)___ Yes ___ No ___N/AAll Other IRB Correspondence ___ Yes ___ No ___N/AAll Sponsor Correspondence ___ Yes ___ No ___N/AAll Study Team Correspondence ___ Yes ___ No ___N/AFDA Form 1572 (all versions)___ Yes ___ No ___N/AAll Monitoring Letters (Site Qualification Letter, Study Initiation Letter, Routine Monitoring Visit Letter, Study Termination Letter)___ Yes ___ No ___N/AMonitoring Visit Log ___ Yes ___ No ___N/AStudy Recruitment Plan___ Yes ___ No ___N/AAll Relevant Standard Operating Procedures___ Yes ___ No ___N/AStep 6: Clinical ReviewEnsure the following documentation is accurate and complete for each study participant. Additionally, be prepared to review and provide support for all source documents. Please contact the JCTO Quality Assurance Unit if you have any questions regarding the items listed below (firstname.lastname@example.org).Item/DocumentationConfirm/CompleteComments/Action ItemsSource Documents/Medical Records___ Yes ___ No ___N/ARelevant SOPs Signed/Dated Informed Consents___ Yes ___ No ___N/ACompleted Case Report Forms___ Yes ___ No ___N/AConfirmed Subject Eligibility ___ Yes ___ No ___N/AProtocol Tests/Evaluations Documented___ Yes ___ No ___N/AAE/SAE Communication with Subject___ Yes ___ No ___N/AAll Data Entry is Current___ Yes ___ No ___N/ALaboratory Tests and Results are Graded and Signed___ Yes ___ No ___N/ALaboratory Normal Ranges___ Yes ___ No ___N/ALaboratory Certificates ___ Yes ___ No ___N/ASpecimen Logs___ Yes ___ No ___N/ACopies of Any Laboratory Audits___ Yes ___ No ___N/ADocumented Premature Study Discontinuation ___ Yes ___ No ___N/AConcomitant/Prohibited medications Documented and Reported___ Yes ___ No ___N/AStudy Drug Accountability Log___ Yes ___ No ___N/ADocumentation of Study Drug Transfers, Returns, and Destruction___ Yes ___ No ___N/AStudy Drug Ordering/Shipping Documentation___ Yes ___ No ___N/AStep 7: Day of InspectionWhen the FDA inspector arrives at the site, he/she will provide official identification/ID badge and present a Notice of Inspection form (FDA Form 482). The table below provides some insight on what to expect during the audit.What to ExpectNotes/Comments/QuestionsPrincipal Investigator and Study Team Meet with FDA InspectorPrincipal Investigator Signs FDA Form 482 (if not presented with a 482, ask for 482)Provide a Tour of the FacilityFDA Inspector will Request to Review Files (Only provide requested files and be prepared to make copies of any requested information. The inspection may take several days, and at the end of each day, the inspector will review relevant findings with the study team which should be communicated with the study sponsor.)FDA Inspector Holds Exit Interview and Reviews Findings (a representative of the Quality Assurance Unit should be present during the exit interview)FDA Inspector Issues FDA Form 483 (Inspectional Observations) for Any DeficienciesStep 8: After InspectionUpon completion of the FDA Inspection please complete the below listed actions. ActionsDate CompletedNotes/CommentsImmediately Notify JCTO, IRB, and Sponsor of All Findings Draft Written Response to FDA Form 483 (if applicable) Send Draft Response to FDA Form 483 to the JCTO Quality Assurance Unit for Review/Approval (if applicable)JCTO Quality Assurance Unit will Review/Approve Response to FDA Form 483 (if applicable)File All FDA Correspondence from Inspection*Note: Please copy the JCTO Quality Assurance Unit on all correspondence with the FDA following the Inspection. The Quality Assurance Unit can assist with preparing the response to the FDA Form 483 and must review/approve the response prior to submission to the FDA. Additional ResourcesFDA Inspection Guidance Document: FDA Information on Running Clinical Trials: FDA Information Sheet Guidance for IRBs, Clinical Investigators, and Sponsors: FDA Clinical Investigator Training Course: CFR - Code of Federal Regulations Title 21: FDA Form 483 Frequently Asked Questions: ................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
- step 1 joint clinical trials office weill cornell
- investigator guidance additional fda obligations
- notes to sponsor investigators df hcc
- sop 400 hub clinical research resources clinical
- responsibilities of an investigator acting as an investigator
- statement of compliance duke university
- fda investigator responsibility checklist
- managing investigational drugs devices
- fda guidance equipment qualification
- uniform guidance for federal awards
- omb uniform guidance for grants
- fda guidance quality system glp
- fda guidance oncology drug development
- fda guidance for industry
- fda guidance ind submission
- fda guidance investigational product label
- fda guidance on ind submissions
- fda guidance dissolution testing
- fda guidance nda submission
- fda guidance quality system